WATERTOWN, MA—Samantha L. Budd Haeberlein, a director at Vigil Neuroscience, Inc. (NASDAQ:VIGL), purchased 12,000 shares of the company's common stock on December 19, according to a recent SEC filing. The purchase comes as the stock trades near its 52-week low of $1.60, having declined over 57% in the past six months. The shares were acquired at a weighted average price of $1.71, with transaction prices ranging from $1.69 to $1.72. This acquisition brings Budd Haeberlein's total holdings to 12,000 shares, valued at approximately $20,520. According to InvestingPro analysis, the stock appears undervalued at current levels, with technical indicators suggesting oversold conditions. Get deeper insights into insider trading patterns and 14 additional ProTips with an InvestingPro subscription.
In other recent news, Vigil Neuroscience has received significant attention in the biotechnology sector due to its advancements in Alzheimer's treatment. The company's VG-3927 program, a potential Alzheimer's treatment, was given the green light by the U.S. Food and Drug Administration (FDA) to potentially increase the drug's exposure limit in its ongoing study. This decision came after Vigil Neuroscience provided a complete response to the FDA, marking a significant step forward for the program.
The company has also been rated Outperform by William Blair and Guggenheim, with William Blair setting a fair value of $18.67 per share. JMP Securities and Mizuho (NYSE:MFG) Securities also maintained their positive ratings, with stock price targets of $23.00 and $13.00 respectively. These ratings reflect the analysts' confidence in Vigil Neuroscience's potential to succeed in the challenging field of neurodegenerative diseases.
Vigil Neuroscience is also making strategic adjustments in its clinical development. The company has decided to forgo an interim analysis for its IGNITE trial, which is assessing the efficacy of iluzanebart in treating a rare neurodegenerative disease, in favor of a comprehensive 12-month final analysis. These recent developments underscore Vigil Neuroscience's commitment to its research initiatives and its potential to address the needs of a broad patient population.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.